Price
Financials
Standalone, Rs crore| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 311 | 306 | 383 | 388 | 408 | 440 | 480 | 526 | 559 | 612 | 579 | 683 |
| Expenses | 258 | 291 | 334 | 349 | 355 | 363 | 394 | 445 | 484 | 567 | 518 | 634 |
| Operating Profit | 53 | 15 | 49 | 38 | 53 | 77 | 86 | 81 | 75 | 45 | 61 | 49 |
| OPM % | 17% | 4.9% | 13% | 10% | 13% | 17% | 18% | 15% | 13% | 7% | 11% | 7% |
| Other Income | 25 | 10 | 9 | -49 | 8 | -26 | 10 | 11 | 1 | 7 | 5 | 9 |
| Interest | 0 | 1 | -0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 2 | 2 |
| Depreciation | 4 | 4 | 4 | 4 | 9 | 9 | 18 | 17 | 3 | 4 | 6 | 5 |
| Profit before tax | 73 | 20 | 54 | -15 | 51 | 42 | 78 | 75 | 73 | 47 | 58 | 51 |
| Tax % | 29% | 23% | 27% | -22% | 25% | 27% | 26% | 25% | 26% | 30% | 23% | 25% |
| Net Profit | 52 | 16 | 39 | -12 | 38 | 31 | 58 | 56 | 54 | 33 | 45 | 38 |
| EPS in Rs | 20.95 | 6.32 | 15.79 | -4.72 | 15.37 | 12.34 | 23.30 | 22.33 | 21.69 | 13.04 | 17.95 | 15.17 |
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 564 | 544 | 571 | 728 | 832 | 814 | 806 | 1,003 | 1,296 | 1,716 | 2,276 | 2,432 |
| Expenses | 547 | 506 | 525 | 657 | 711 | 678 | 719 | 838 | 1,111 | 1,462 | 2,014 | 2,202 |
| Operating Profit | 16 | 37 | 46 | 71 | 121 | 135 | 86 | 165 | 184 | 254 | 262 | 230 |
| OPM % | 2.9% | 7% | 8% | 10% | 15% | 17% | 11% | 16% | 14% | 15% | 12% | 9% |
| Other Income | 7 | 14 | 12 | 16 | 13 | 13 | 15 | -14 | 51 | -56 | 23 | 21 |
| Interest | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 4 | 6 |
| Depreciation | 17 | 16 | 15 | 15 | 19 | 20 | 17 | 16 | 15 | 40 | 29 | 17 |
| Profit before tax | 6 | 36 | 44 | 73 | 114 | 127 | 83 | 134 | 220 | 156 | 252 | 228 |
| Tax % | 9% | 44% | 41% | 25% | 37% | 27% | 26% | 26% | 26% | 26% | 26% | |
| Net Profit | 5 | 20 | 26 | 54 | 72 | 93 | 62 | 99 | 162 | 116 | 188 | 170 |
| EPS in Rs | 2.10 | 8.02 | 10.36 | 21.78 | 28.88 | 37.32 | 24.64 | 39.72 | 64.60 | 46.30 | 75.01 | 67.85 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 3% | 5% | 41% | 40% | 37% | 69% | 48% |
| 10 Years | 5 Years | 3 Years | TTM | 1 Year | Last Year | |
|---|---|---|---|---|---|---|
| Compounded Sales Growth | 15% | 23% | 31% | 31% | ||
| Compounded Profit Growth | 43% | 16% | 15% | -18% | ||
| Stock Price CAGR | 21% | 15% | 12% | -31% | ||
| Return on Equity | 21% | 22% | 23% | 23% |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 |
| Reserves | 146 | 151 | 218 | 242 | 296 | 359 | 451 | 506 | 584 | 707 | 765 | 868 |
| Borrowings | 0 | 0 | 0 | 0 | 0 | 12 | 12 | 9 | 7 | 5 | 36 | 111 |
| Other Liabilities | 261 | 247 | 193 | 214 | 261 | 330 | 306 | 337 | 389 | 362 | 712 | 1,006 |
| Total Liabilities | 412 | 403 | 415 | 461 | 562 | 706 | 775 | 857 | 985 | 1,078 | 1,518 | 1,989 |
| Fixed Assets | 101 | 97 | 87 | 75 | 75 | 72 | 81 | 74 | 69 | 67 | 64 | 117 |
| CWIP | 12 | 6 | 5 | 4 | 7 | 24 | 4 | 2 | 1 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 298 | 299 | 324 | 382 | 480 | 611 | 690 | 780 | 915 | 1,011 | 1,454 | 1,872 |
| Total Assets | 412 | 403 | 415 | 461 | 562 | 706 | 775 | 857 | 985 | 1,078 | 1,518 | 1,989 |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity | -46 | 57 | 38 | 9 | 55 | 87 | 105 | 101 | 58 | 28 | 65 | -15 |
| Cash from Investing Activity | -19 | -4 | 0 | -9 | 4 | -171 | 173 | 5 | 18 | 22 | 31 | 19 |
| Cash from Financing Activity | 0 | -1 | 0 | 0 | 0 | -6 | -9 | -9 | -24 | -44 | -66 | -92 |
| Net Cash Flow | -64 | 53 | 38 | -1 | 59 | -90 | 269 | 96 | 52 | 5 | 31 | -88 |
| Free Cash Flow | -69 | 48 | 33 | 3 | 37 | 74 | 99 | 94 | 53 | 18 | 64 | -18 |
| CFO/OP | 393% | 365% | 133% | 28% | 126% | 100% | 101% | 146% | 60% | 46% | 51% | 26% |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 30 | 54 | 29 | 35 | 40 | 37 | 38 | 39 | 39 | 43 | 39 | 34 |
| Inventory Days | 157 | 141 | 121 | 229 | 186 | 197 | 198 | 164 | 193 | 140 | 208 | 272 |
| Days Payable | 203 | 174 | 184 | 257 | 266 | 251 | 221 | 223 | 231 | 121 | 173 | 207 |
| Cash Conversion Cycle | -16 | 21 | -34 | 7 | -39 | -17 | 15 | -20 | 1 | 62 | 74 | 99 |
| Working Capital Days | -15 | -28 | -36 | -8 | -14 | -16 | -17 | -34 | -18 | 20 | 22 | 50 |
| ROCE % | -13% | 4% | 15% | 19% | 27% | 34% | 30% | 16% | 31% | 31% | 33% | 29% |
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoters | 75.00% | 75.00% | 75.00% | 75.00% | 75.00% | 75.00% | 75.00% | 75.00% | 75.00% | 75.00% | 75.00% | 75.00% |
| FIIs | 2.69% | 2.66% | 2.73% | 2.79% | 2.90% | 2.92% | 2.89% | 3.03% | 2.74% | 2.71% | 2.78% | 2.68% |
| DIIs | 2.42% | 2.76% | 3.77% | 4.99% | 5.08% | 5.21% | 4.65% | 4.55% | 5.26% | 5.55% | 5.79% | 6.08% |
| Public | 19.89% | 19.57% | 18.50% | 17.21% | 17.02% | 16.85% | 17.45% | 17.41% | 17.00% | 16.73% | 16.42% | 16.24% |
| No. of Shareholders | 32,380 | 29,032 | 29,418 | 27,169 | 27,615 | 27,322 | 32,466 | 34,378 | 32,914 | 31,551 | 29,007 | 29,338 |
Fundamentals
Market Cap₹ 15,636 Cr.
Current Price₹ 6,254
Stock P/E90.1
Book Value₹ 349
ROCE29.3 %
ROE23.3 %
Dividend Yield0.58 %
Face Value₹ 2.00
Compounded Sales Growth (TTM)31%
Compounded Profit Growth (TTM)-18%
Standalone figures.
Valuation
Market capRs 15,078 Cr
Enterprise valueRs 14,740 Cr
P/E (TTM)88.89x
Price to book17.28x
Price to sales6.20x
EV / EBITDA58.67x
EV / EBIT63.00x
EV / sales6.06x
Earnings yield1.12%
Dividend yield0.60%
P/E, 3-year average123.98x
P/B, 3-year average22.96x
P/E, 5-year average111.48x
P/B, 5-year average19.04x
Profitability
Operating margin (excl. other income)11.51%
Operating margin (incl. other income)12.54%
EBITDA margin10.33%
Pre-tax margin9.38%
Net profit margin6.97%
Net margin, latest quarter5.56%
ROE22.82%
ROCE28.69%
ROA10.69%
ROE, 3-year average21.09%
ROCE, 3-year average27.69%
ROA, 3-year average11.76%
ROE, 5-year average18.81%
ROCE, 5-year average24.84%
ROA, 5-year average10.72%
ROIC (approx.)32.53%
Tax rate25.65%
Other income / net worth2.66%
Growth
Sales growth (latest year)32.59%
Profit growth (latest year)62.02%
Sales CAGR, 3 years31.40%
Sales CAGR, 5 years22.84%
Profit CAGR, 3 years23.61%
Profit CAGR, 5 years14.98%
Sales growth QoQ18.01%
Profit growth QoQ-15.49%
Sales growth YoY (latest quarter)29.73%
Profit growth YoY (latest quarter)-32.06%
Per share
EPS (TTM)Rs 67.85
EPS (latest year)Rs 75.01
EPS (latest quarter)Rs 15.17
EPS, 3-year averageRs 61.97
EPS, 5-year averageRs 50.05
Book value per shareRs 349.12
Sales per shareRs 972.82
Cash flow per shareRs -6.06
Free cash flow per shareRs -7.20
Dividend per share (latest year)Rs 36.00
Dividend per share, 3-year averageRs 30.67
Dividend per share, 5-year averageRs 23.60
Dividends
Dividend payout47.99%
Dividend payout, 3-year average51.42%
Dividend payout, 5-year average47.03%
Efficiency
Asset turnover1.14x
Fixed asset turnover19.37x
Inventory turnover1.37x
Inventory days267 days
Debtor days34 days
Debtors turnover10.65x
Creditor days207 days
Cash conversion cycle99 days
Working capital days50 days
Leverage
Total debtRs 111 Cr
Cash and bankRs 449 Cr
Net debtRs -338 Cr
Debt to equity0.13x
Net debt / EBITDA-1.35x
Interest coverage40.90x
Current ratio (filing 2026-03-31)1.76x
Quick ratio (filing 2026-03-31)0.72x
Trade payables (filing 2026-03-31)Rs 783 Cr
Owners' fund to total sources43.88%
Debt to assets5.56%
Cash flow
Cash from Operating Activity (latest year)Rs -15 Cr
Cash from Investing Activity (latest year)Rs 19 Cr
Cash from Financing Activity (latest year)Rs -92 Cr
Net Cash Flow (latest year)Rs -88 Cr
Free cash flow (latest year)Rs -18 Cr
FCFE (approx.: FCF + change in debt)Rs 57 Cr
Cash from ops / profit, 5 years0.38x
Statement figures
Net sales (TTM)Rs 2,432 Cr
Net sales (latest year)Rs 2,276 Cr
Sales (latest quarter)Rs 683 Cr
Operating profit excl. other income (latest year)Rs 262 Cr
Operating profit (latest quarter)Rs 49 Cr
Other income (TTM)Rs 21 Cr
EBITDA (TTM)Rs 251 Cr
PBDT (TTM)Rs 245 Cr
Profit before tax (TTM)Rs 228 Cr
Tax (latest year)Rs 65 Cr
Net profit (TTM)Rs 170 Cr
Net profit (latest year)Rs 188 Cr
Net profit (latest quarter)Rs 38 Cr
Depreciation (TTM)Rs 17 Cr
Depreciation (latest quarter)Rs 5 Cr
Interest (TTM)Rs 6 Cr
Cost of goods sold (latest year)Rs 1,404 Cr
Total expenditure (latest year)Rs 2,014 Cr
Total income (latest year)Rs 2,299 Cr
Share capitalRs 5 Cr
ReservesRs 868 Cr
Shareholders' fundsRs 873 Cr
Total assetsRs 1,989 Cr
Net blockRs 117 Cr
ReceivablesRs 214 Cr
InventoryRs 1,027 Cr
Other liabilitiesRs 1,006 Cr
Shares outstanding (crore)2.50
Ownership
Promoter holding75.00% (+0.00 in a year)
Computed by MarketFriction from the standalone statements. Returns use average balances.
P/E 88.9 is at the 11th percentile of its own 9.4-year range
(median 122.8, low 68.4, high 227.5).
P/B 17.28 is at the 38th percentile (median 19.94).
Monthly. Market cap from split-adjusted price; profit and book value as reported by that month. A low percentile means cheap versus its own history, not cheap versus peers.
| Period | ASTRAZEN | Nifty 50 | Difference |
|---|---|---|---|
| 1 week | -8.5% | -2.8% | -5.7 pts |
| 1 month | -12.8% | -6.8% | -6.0 pts |
| 3 months | -27.4% | -7.6% | -19.8 pts |
| 6 months | -22.3% | +0.4% | -22.7 pts |
| 1 year | -33.2% | -9.9% | -23.3 pts |
| 2 years | -10.6% | -13.6% | +2.9 pts |
| 3 years | +33.9% | +14.2% | +19.8 pts |
| 5 years | +94.7% | +27.9% | +66.8 pts |
32 mutual fund schemes hold about ₹1,277 Cr.
Over three months 29 bought more and 2 sold (share counts, price move removed).
| Fund | Weight | Est. Cr | 3m shares |
|---|---|---|---|
| Nippon India Small Cap Fund | 0.56% | 460 | +11% |
| ICICI Pru Healthcare Fund- | 1.99% | 139 | +232% |
| Bandhan Large & Mid Cap Fund | 0.52% | 110 | +13% |
| Bandhan Innovation Fund | 2.72% | 72 | +8% |
| ICICI Pru Quality Fund | 2.63% | 56 | +17% |
| ICICI Pru Multi Cap Fund | 0.28% | 54 | +202% |
| ICICI Pru Multi Cap Fund | 0.28% | 52 | +202% |
| ICICI Pru Innovation Fund | 0.66% | 52 | +100% |
| Nippon India Pharma Fund | 0.46% | 43 | +11% |
| ICICI Pru Small Cap Fund | 0.24% | 24 | +11% |
| ICICI Pru Small Cap Fund | 0.24% | 23 | +11% |
| Baroda BNP Paribas Small Cap Fund | 1.71% | 22 | +12% |
| Bandhan Small Cap Fund | 0.06% | 21 | -2% |
| Bandhan Aggressive Hybrid Fund | 0.78% | 20 | +12% |
| Baroda BNP Paribas Health and Wellness Fund | 3.56% | 18 | +27% |
| Baroda BNP Paribas Manufacturing Fund | 1.91% | 16 | +17% |
| UTI MNC Fund | 0.53% | 15 | +13% |
| Bandhan Large Cap Fund | 0.57% | 12 | +15% |
| ICICI Pru Retirement Fund-Hybrid Aggressive Plan | 0.97% | 12 | +9% |
| ICICI Pru Manufacturing Fund | 0.13% | 9 | +19% |
| ICICI Pru MNC Fund | 0.44% | 8 | +13% |
| ICICI Pru ESG Exclusionary Strategy Fund | 0.48% | 7 | +15% |
| Baroda BNP Paribas Innovation Fund | 0.68% | 6 | +67% |
| ICICI Pru Retirement Fund-Pure Equity Plan | 0.26% | 6 | +8% |
| ICICI Pru Children's Fund | 0.34% | 5 | +15% |
Red flags
F-score 4 of 8| explain | Weak cash conversion Cash from operations was 17% of net profit over the last 3 years |
| explain | High accruals Profit exceeded operating cash by 10% of total assets in 2026 |
| look | Inventory outrunning sales Inventory grew 87% vs sales +33% in 2026 |
| look | Regulator order or action Regulator order or action 2026-09-18: AstraZeneca Pharma India Limited has informed the Exchange about Action(s) taken or orders passed |
Checks on the latest reported years: cash vs profit, accruals, receivables and inventory vs sales, dilution, debt, interest cover, equity, other income, losses, and auditor, top-management, insolvency and regulator filings in the last 12 months. A flag asks for an explanation; it is not a verdict.
Latest quarter
Jun 2026Sales ₹683 Cr +29.8% vs Jun 2025.
Net profit ₹38 Cr -32.1%.
Against our estimate for Jun 2026: sales -0.0%, profit -36.2% miss. Our estimate for Sep 2026: sales Rs 700 Cr, profit Rs 47 Cr (how).
Activity
Compare| Company | Mcap (Cr) | P/E | ROCE |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | 447,476 | 35.4 | 20.5 % |
| Divis Laboratories Ltd | 250,363 | 84.0 | 22.0 % |
| Torrent Pharmaceuticals Ltd | 186,152 | 83.4 | 15.2 % |
| Zydus Lifesciences Ltd | 119,750 | 24.6 | 21.1 % |
| Cipla Ltd | 111,430 | 31.1 | 15.5 % |
| Laurus Labs Ltd | 106,928 | 97.8 | 17.8 % |
| Mankind Pharma Ltd | 105,120 | 49.3 | 13.5 % |
| Dr Reddys Laboratories Ltd | 104,494 | 32.4 | 13.0 % |
| Aurobindo Pharma Ltd | 97,682 | 25.8 | 12.9 % |
| Lupin Ltd | 93,840 | 15.8 | 29.9 % |
| Glenmark Pharmaceuticals Ltd | 68,905 | 22.1 | 39.8 % |
| Alkem Laboratories Ltd | 62,772 | 27.6 | 21.2 % |
| Biocon Ltd | 61,439 | 84.5 | 3.61 % |
| Abbott India Ltd | 57,949 | 35.9 | 44.8 % |
| Gland Pharma Ltd | 49,333 | 43.1 | 15.1 % |
No bulk or block deals on record.
| Ex-date | Action | Factor |
|---|---|---|
| 2026-07-31 | Dividend - Rs 36 Per Share | |
| 2025-07-18 | Dividend - Rs 32 Per Share | |
| 2024-07-05 | Dividend - Rs 24 Per Share | |
| 2023-07-14 | Dividend - Rs 16 Per Share | |
| 2022-07-07 | Dividend - Rs 8 Per Share | |
| 2021-08-18 | Interim Dividend - Rs 2 Per Share | |
| 2020-08-20 | Interim Dividend - Rs 2 Per Share | |
| 2019-08-20 | Interim Dividend - Re 1 Per Share | |
| 2018-08-30 | Annual General Meeting | |
| 2017-09-04 | Annual General Meeting | |
| 2016-08-02 | Annual General Meeting | |
| 2015-08-20 | Annual General Meeting | |
| 2014-09-18 | Annual General Meeting | |
| 2013-08-07 | Annual General Meeting | |
| 2011-07-07 | Dividend-Rs.10/- Per Share | |
| 2010-05-06 | Dividend-Rs.10/- Pr Share | |
| 2009-04-29 | Agm/Div-Rs.15/- Per Share | |
| 2008-04-11 | Agm/Div-Rs15 Per Share | |
| 2008-01-04 | Sch Of Agmt- Bonus Deb1:1 | |
| 2007-04-25 | Agm Bc Start Date/Purpose Revised | |
| 2007-03-22 | Int Div-Rs.12/- Per Sharepurpose Revised | |
| 2006-06-15 | Fv Split Rs.10/- To Rs.2/ | 0.2000 |
| 2006-04-12 | Agm/Fin Div-Rs.20 Per Sh |
Company filings to NSE, newest first. Routine notices (trading window, newspaper copies) are left out. Click a row for the filing.
No short selling reported to NSE in our files.
Short sales disclosed by brokers to NSE, by trade date. Collected since late September 2026.
Scrip PE is greater than 50 (4 trailing quarters)
Quick answers
What is the market cap of Astrazeneca Pharma India Ltd?
Astrazeneca Pharma India Ltd (ASTRAZEN) has a market capitalisation of Rs 15,636 Cr. at the 2026-10-01 close.
What is the P/E ratio of Astrazeneca Pharma India Ltd?
Astrazeneca Pharma India Ltd trades at a P/E of 90.1 on trailing twelve-month profit, at the 2026-10-01 close.
What were Astrazeneca Pharma India Ltd's latest quarterly results?
In the Jun 2026 quarter, Astrazeneca Pharma India Ltd sales was Rs 683 Cr (+29.8% vs Jun 2025) and net profit was Rs 38 Cr.
What is the 52-week high and low of Astrazeneca Pharma India Ltd?
The 52-week high is Rs 9,849.50 and the 52-week low is Rs 6,120.50.